The authors conducted a multicenter, non-randomized, open label, phase II trial to evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC). The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC.

READ FULL ARTICLE Curated publisher From Mdlinx